Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- US District Court Rejects Claim for Myrbetriq Patent Infringement, Astellas to Challenge Ruling
June 13, 2023
- Shionogi Kicks Off Global PEP Study of Xocova; NDA for Full Approval Filed in Japan
June 12, 2023
- Astellas Files Zolbetuximab for CLDN18.2-Positive Gastric Cancer in Japan
June 12, 2023
- ASKA, RaQualia Wind Up Ion Channels Collab
June 12, 2023
- AstraZeneca Crowned in Foreign Pharma Ranking for 2nd Year Straight, Followed by MSD
June 9, 2023
- Ceolia Pharma’s Comlex Otic Solution Now Available in Japan
June 9, 2023
- Takeda Rolls Out Low-Dose Form of SBS Therapy Revestive in Japan
June 9, 2023
- Lecanemab Filed for Approval in South Korea: Eisai/Biogen
June 9, 2023
- Astellas Grabs Rights to Kate’s XLMTM Gene Therapy
June 9, 2023
- Opdivo Top-Seller Drug in Japan for 17 Months on End: Encise
June 8, 2023
- Japan Ethical Drug Sales Up 1.4% in April: Crecon
June 8, 2023
- Enhertu Nets Favorable Data in Pan-Tumor Trial for HER2 Solid Cancers
June 7, 2023
- Positive PIb Data Unveiled for TROP2 ADC Plus Keytruda: Daiichi Sankyo/AZ
June 7, 2023
- Mounjaro, Dayvigo Again Top Sales Rep Promotion Rankings for GPs, HPs in April
June 7, 2023
- Japan Firms Joining Fray in siRNA Drug Development; Takeda Could File as Early as FY2025
June 6, 2023
- Japan Approves 1st Gene Panel Testing for IRD
June 6, 2023
- Xocova Given to Over 50,000 Patients in 6 Months: Shionogi
June 6, 2023
- Pfizer Japan Seeks Lupus Nephritis Nod for Rituxan Biosimilar
June 6, 2023
- Kaken, Dong-Wha Ink License Pact for Ecclock in South Korea
June 6, 2023
- Gilead Files HIV Med Lenacapavir in Japan
June 5, 2023
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…